Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Capricor Therap (CAPR)

Capricor Therap (CAPR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 88,166
  • Shares Outstanding, K 19,724
  • Annual Sales, $ 1,010 K
  • Annual Income, $ -7,640 K
  • 60-Month Beta 6.83
  • Price/Sales 89.30
  • Price/Cash Flow N/A
  • Price/Book 2.83
Trade CAPR with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +232,425.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.16 +7.69%
on 10/21/20
5.60 -20.00%
on 09/28/20
-0.82 (-15.47%)
since 09/25/20
3-Month
4.16 +7.69%
on 10/21/20
12.32 -63.64%
on 07/28/20
-3.24 (-41.97%)
since 07/24/20
52-Week
0.88 +409.09%
on 03/12/20
12.32 -63.64%
on 07/28/20
+1.84 (+69.70%)
since 10/25/19

Most Recent Stories

More News
Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020

--Final 12-Month Results from Phase II Trial to be Presented on October 1--

CAPR : 4.47 (unch)
Capricor Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Capricor Therapeutics ("Capricor") (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention...

CAPR : 4.47 (unch)
Capricor Therapeutics to Present at The LD 500 Virtual Conference

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / Capricor Therapeutics ("Capricor") (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based...

CAPR : 4.47 (unch)
Thinking about buying stock in Sigma Labs Inc. Common Stock, Viveve Medical Inc, Ovid Therapeutics Inc, Capricor Therapeutics Inc, or Immunovant Inc?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SGLB, VIVE, OVID, CAPR, and IMVT.

CAPR : 4.47 (unch)
OVID : 5.30 (-0.75%)
SGLB : 2.50 (+2.46%)
VIVE : 0.5200 (-3.67%)
Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19

- The INSPIRE Trial is a Randomized, Placebo-Controlled, Multi-Center Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 -

CAPR : 4.47 (unch)
Capricor: 2Q Earnings Snapshot

BEVERLY HILLS, Calif. (AP) _ Capricor Therapeutics Inc. (CAPR) on Thursday reported a loss of $3.5 million in its second quarter.

CAPR : 4.47 (unch)
Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Exosome Platform for COVID-19

CAPR : 4.47 (unch)
Thinking about buying stock in Lakeland Industries, Capricor Therapeutics, T2 Biosystems, Callon Petroleum, or TOP Ships?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LAKE, CAPR, TTOO, CPE, and TOPS.

CPE : 5.02 (-5.28%)
CAPR : 4.47 (unch)
LAKE : 25.03 (+2.00%)
Capricor to Participate in BIO Digital International Convention

Management to Host One-on-One Partnering Meetings

CAPR : 4.47 (unch)
Capricor to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020

Capricor Therapeutics ("Capricor") (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases,...

CAPR : 4.47 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based...

See More

Key Turning Points

2nd Resistance Point 4.69
1st Resistance Point 4.58
Last Price 4.47
1st Support Level 4.34
2nd Support Level 4.21

See More

52-Week High 12.32
Fibonacci 61.8% 7.95
Fibonacci 50% 6.60
Fibonacci 38.2% 5.25
Last Price 4.47
52-Week Low 0.88

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar